Current Neuro-Oncology
Volume
26 Number 15
31 July 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 15, 31 July
Chavana AN, Taylor ZL, DeGroote N, Lindsay HB, Sauer HE, Mason EJ,
Schafer ES, Miller TP, Castellino SM, Pommert L, O'Brien MM,
Ramsey LB, Bernhardt MB, Brown AL.
Toxicity
profile of high-dose methotrexate in young children with central
nervous system tumors.
Pediatr
Blood Cancer. 2024 Jul 22:e31213. doi:
10.1002/pbc.31213. PMID:
39039774. Observational study˰
ˍ
Haisraely O, Sivan M, Symon Z, Ben-Ayun M, Tsvang L, Kraitman J,
Dubinsky S, Siman-Tov M, Benjamin D, Lawrence Y, Cohen Z, Wohl A,
Kaisman-Elbaz T, Taliansky A.
Dose
escalation with simultaneous integrated boost for un-methylated
multiple glioblastoma.
Rep Pract Oncol Radiother.
2024 Jul 22;29(3):290-293. doi:
10.5603/rpor.100385. PMID:
39144267. Observational
study. ˍ
Liu X, Zhang X, Fan Y, Wang B, Wang J, Zeng M, Li S, Shen M, Zhang
W, Sessler DI, Peng Y.
Intraoperative
goal-directed fluid management and postoperative brain edema in
patients having high-grade gliomas resections: a randomized trial.
Int
J Surg. 2024 Jul 22. doi:
10.1097/JS9.0000000000001969. PMID:
39037734. Interventional study. ˍ
Zhang J, Qiu X, Feng J, Liu Y.
MGMT
promoter methylation is a strong prognostic factor for survival
after progression in high-grade gliomas.
Chin
Neurosurg J. 2024 Jul 24;10(1):24. doi:
10.1186/s41016-024-00375-2. PMID:
39049072. Observational study. ˍ
Yucel B, Aslan D, Yaprak G, Guney Y, Erpolat P, Cetinayak O,
Kayali FI, Eroglu C, Isik N, Erdis E.
Survival
and Prognostic Factors in Re-irradiation for Recurrent/Progressive
Malignant Gliomas: Turkish Society of Radiation Oncology
Neuro-Oncology Group, TROD 007-006 Study.
Turk
Neurosurg. 2024 Jul 25. doi:
10.5137/1019-5149.JTN.44460-23.2. PMID:
39087286. Observational study. ˍ
Al-Khatib SM, Al-Bzour AN, Almajali MN, Jarrad TA, Al-Eitan LN,
Abdo N.
Analysis of IDH and EGFR as
biomarkers in glioblastoma multiforme: A case-control study.
Heliyon.
2024 Jul 26;10(15):e35323. doi:
10.1016/j.heliyon.2024.e35323. PMID:
39165999. Observational study. ˍ
Horowitz MA, Ghadiyaram A, Mehkri Y, Chakravarti S, Liu J, Fox K,
Gendreau J, Mukherjee D.
Surgical
resection of glioblastoma in the very elderly: An analysis of
survival outcomes using the surveillance, epidemiology, and end
results database.
Clin
Neurol Neurosurg. 2024 Jul 26;245:108469. doi:
10.1016/j.clineuro.2024.108469. PMID:
39079287. Observational study˰
ˍ
Kurdi N, Mokánszki A, Balogh I, Ujfalusi A, Szabó S,
Méhes G, Bedekovics J.
Extracranial
metastatic oligodendroglioma with molecular progression, case
presentation.
Diagn
Pathol. 2024 Jul 26;19(1):103. doi:
10.1186/s13000-024-01529-7. PMID:
39061087. Case report. ˍ
Toh TB, Thng DKH, Bolem N, Vellayappan BA, Tan BWQ, Shen Y, Soon
SY, Ang YLE, Dinesh N, Teo K, Nga VDW, Low SW, Khong PL, Chow EK,
Ho D, Yeo TT, Wong ALA.
Evaluation of
ex vivo drug combination optimization platform in recurrent high
grade astrocytic glioma: An interventional, non-randomized,
open-label trial protocol.
PLoS
One. 2024 Jul 26;19(7):e0307818. doi:
10.1371/journal.pone.0307818. PMID:
39058662. Interventional study protocol. ˍ
Cappelli L, Uppendahl A, Gardner C, Khan M, Kayne A, Vemula S,
Poiset SJ, Zhan T, Judy KD, Andrews DW, Simone NL, Alnahhas I, Shi
W.
Baseline single institutional
retrospective review of body mass index (BMI) as a prognostic
indicator in patients with newly diagnosed glioblastoma (GBM).
J
Clin Neurosci. 2024 Jul 27;127:110754. doi:
10.1016/j.jocn.2024.07.015? PMID:
39068727. Observational study˰
ˍ
Goldlust SA, Singer S, Cappello LA, AlMekkawi AK, Lee KD, Ingenito
AC, Lewis BE, Nyirenda T, Azmi H, Kaptain GJ.
Phase
1 study of concomitant tumor treating fields and temozolomide
chemoradiation for newly diagnosed glioblastoma.
Neurooncol
Adv. 2024 Jul 29;6(1):vdae129. doi:
10.1093/noajnl/vdae129. PMID:
39211521. Interventional study.ˍ
Lee Y, Lee E, Roh TH, Kim SH.
Bevacizumab
Alone Versus Bevacizumab Plus Irinotecan in Patients With
Recurrent Glioblastoma: A Nationwide Population-Based Study.
J
Korean Med Sci. 2024 Jul 29;39(34):e244. doi:
10.3346/jkms.2024.39.e244. PMID:
39228184. Observational study. ˍ
Pichler J, Traub-Weidinger T, Spiegl K, Imamovic L, Braat AJAT,
Snijders TJ, Verhoeff JJC, Flamen P, Tauchmanova L, Hayward C,
Kluge A.
Results from a phase I study
of 4-L-[131I]iodo-phenylalanine
([131I]IPA)
with external radiation therapy in patients with recurrent
glioblastoma (IPAX-1).
Neurooncol
Adv. 2024 Jul 29;6(1):vdae130. doi:
10.1093/noajnl/vdae130. PMID:
39211520. Interventional study. ˍ
Priesterbach-Ackley LP, Cordier F, de Witt Hamer P, Snijders TJ,
Robe PA, Küsters B, de Leng WWJ, den Dunnen WFA, Brandsma D,
Jansen C, Wesseling P, Muhlebner A.
Diffuse,
IDH-wildtype gliomas in adults with minimal histological change
and isolated TERT promoter mutation: not simply CNS WHO grade 4.
Acta
Neuropathol. 2024 Jul 29;148(1):12. doi:
10.1007/s00401-024-02773-3. PMID:
39073427. Case report. ˍ
Janssen JBE, Brahm CG, Driessen CML, Nuver J, Labots M,
Kouwenhoven MCM, Sanchez Aliaga E, Enting RH, de Groot JC,
Walenkamp AME, van Linde ME, Verheul HMW.
The
STELLAR trial: a phase II/III randomized trial of high-dose,
intermittent sunitinib in patients with recurrent glioblastoma.
Brain
Commun. 2024 Jul 30;6(4):fcae241. doi:
10.1093/braincomms/fcae241. PMID:
39114330. Interventional study. ˍ
Natsume K, Yoshida A, Sakakima H, Yonezawa H, Kawamura K, Akihiro
S, Hanaya R, Shimodozono M.
Age-independent
benefits of postoperative rehabilitation during chemoradiotherapy
on functional outcomes and survival in patients with glioblastoma.
J
Neurooncol. 2024 Jul 30. doi:
10.1007/s11060-024-04785-1. PMID:
39078543. Observational study. ˍ
Tataranu LG, Staicu GA, Dricu A, Turliuc S, Paunescu D, Kamel A,
Rizea RE.
Combined Statistical Analysis
of Glioblastoma Outcomes-A Neurosurgical Single-Institution
Retrospective Study.
Medicina
(Kaunas). 2024 Jul 30;60(8):1234. doi:
10.3390/medicina60081234. PMID:
39202515. Observational study. ˍ
Biau J, Durando X, Boux F, Molnar I, Moreau J, Leyrat B, Guillemin
F, Lavielle A, Cremillieux Y, Seddik K, Dufort S, De Beaumont O,
Thivat E, Le Duc G.
NANO-GBM trial of
AGuIX nanoparticles with radiotherapy and temozolomide in the
treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and
MRI-based biodistribution.
Clin
Transl Radiat Oncol. 2024 Jul 31;48:100833. doi:
10.1016/j.ctro.2024.100833. PMID:
39184998. Interventional study. ˍ
Lim-Fat MJ, Cotter JA, Touat M, Vogelzang J, Sousa C, Pisano W,
Geduldig J, Bhave V, Driver J, Kao PC, McGovern A, Ma C, Margol
AS, Cole K, Smith A, Goldman S, Kaneva K, Truong AL, Nazemi KJ,
Wood MD, Wright KD, London WB, Warren KE, Wen PY, Bi WL,
Alexandrescu S, Reardon DA, Ligon KL, Yeo KK.
A
comparative analysis of IDH-mutant glioma in pediatric, young
adult, and older adult patients.
Neuro
Oncol. 2024 Jul 31:noae142. doi:
10.1093/neuonc/noae142. PMID:
39082676. Observational study˰
ˍ
Xiao Y, Zhao Y, Cheng X, Hao P, Tian Y, He J, Wang W, Chen L, Feng
Y, Li T, Peng L, Chong W, Fang F, Zhang Y.
Association
between Postoperative Decrease of Albumin and Outcomes in Patients
Undergoing Craniotomy for Brain Tumors.
World
Neurosurg. 2024 Jul 31:S1878-8750(24)01316-0. doi:
10.1016/j.wneu.2024.07.176. PMID:
39094936. Observational study˰
ˍ